Clinical Study

The Prognostic Value of Lymph Nodes Dissection Number on Survival of Patients with Lymph Node-Negative Gastric Cancer

Wu Song, Yujie Yuan, Liang Wang, Weiling He, Xinhua Zhang, Chuangqi Chen, Changhua Zhang, Shirong Cai, and Yulong He

Department of Gastrointestinal and Pancreatic Surgery, The First Affiliated Hospital of Sun Yat-sen University, 582nd Zhongshan Road, Guangzhou 510080, China

Correspondence should be addressed to Yulong He; yulongh.sysu@gmail.com

Received 7 February 2014; Accepted 2 April 2014; Published 24 April 2014

Academic Editor: Sergio Morini

Copyright © 2014 Wu Song et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. The study was designed to explore the prognostic value of examined lymph node (LN) number on survival of gastric cancer patients without LN metastasis. Methods. Between August 1995 and January 2011, 300 patients who underwent gastrectomy with D2 lymphadenectomy for LN-negative gastric cancer were reviewed. Patients were assigned to various groups according to LN dissection number or tumor invasion depth. Some clinical outcomes, such as overall survival, operation time, length of stay, and postoperative complications, were compared among all groups.

Results. The overall survival time of LN-negative GC patients was 50.2±30.5 months. Multivariate analysis indicated that LN dissection number (P<0.001) and tumor invasion depth (P<0.001) were independent prognostic factors of survival. The number of examined LNs was positively correlated with survival time (P<0.05) in patients with same tumor invasion depth but not correlated with T1 stage or examined LNs >30. Besides, it was not correlated with operation time, transfusion volume, length of postoperative stay, or postoperative complication incidence (P>0.05).

Conclusions. The number of examined lymph nodes is an independent prognostic factor of survival for patients with lymph node-negative gastric cancer. Sufficient dissection of lymph nodes is recommended during surgery for such population.

1. Introduction

Gastric cancer (GC) is one of the most prevalent death-related cancers all over the world. Surgical resection combined with lymphadenectomy is a pivotal treatment for GC patients. From 1997 to 2002, the International Union Against Cancer (UICC) and the American Joint Committee on Cancer (AJCC) have established the lymph node (LN) classification of GC, which is mainly based on the number of metastatic lymph nodes (LNs) [1, 2]. It is required that at least 15 LNs must be dissected to achieve an accurate evaluation of N classification [3]. However, with this classification, the deviation of pathological TNM stage from clinical TNM stage still occurred in 10–15% of GC cases.

According to the 7th edition of UICC/AJCC TNM system, regardless of total number of excised LNs, N0 classification is defined as the negative LNs metastasis [1]. The system also indicates that the N classification actually depends on the number of positive LNs, rather than the number of examined LNs [4]. However, several studies have suggested that the total number of excised LNs is potentially related to the stage and prognosis of GC [5, 6].

To obtain a reliable assessment of N classification for GC patients, the UICC/AJCC recommends that at least 15 LNs should be dissected during surgery, irrespective of LN location [7, 8]. Although previous findings indicate that D2 lymphadenectomy with at least 15 LNs excised could provide a reliable prognosis for curable gastric cancer, it remains unclear whether the number of dissected LNs is correlated with clinical outcomes of lymph node-negative GC [9]. Hence, this study was designed to explore the relationship between the total number of examined LNs during surgery and the prognosis of GC without LN metastasis.

2. Patients and Methods

2.1. Patients. From August 1995 to January 2011, a total of 300 patients who had curable gastric cancer and underwent
radical gastrectomy at our single center were retrospectively reviewed. Inclusion criteria were listed as follows. (1) Primary adenocarcinoma was confirmed histopathologically. (2) No lymph node or distant metastasis (any T stage, N0, and M0) was reported in final pathological diagnosis. (3) No history of gastrectomy or other malignancies was detected via reviewing medical records. Patients who suffered from advanced gastric cancer would receive additional chemotherapy prior to surgery, with alkylating drugs and fluorouracil as main chemotherapeutic agents. The clinicopathological characteristics of all patients were collected from our medical database. The protocol of current study was approved by the Research Ethics Committee of Sun Yat-sen University, with informed consent obtained from all patients or their legal representatives.

2.2. Methods

2.2.1. Surgical Treatment. All patients who underwent radical gastrectomy plus D2 lymphadenectomy were included in final analysis. A curative tumor resection was defined as macroscopic removal of all visible tumors and metastatic LNs, with pathologically negative resection margins of 6–8 cm (R0 resection) achieved. Subtotal (proximal or distal) or total gastrectomy was selected according to the individual condition during surgery. Billroth I reconstruction was performed after a proximal gastrectomy, while Billroth II fashion was applied after a distal gastrectomy. Roux-en-Y anastomosis between esophagus and small intestine was applied after a total gastrectomy.

Primary tumors were resected en bloc with D2 lymphadenectomy according to the Japanese Gastric Cancer Association guidelines. D2 lymphadenectomy involves the removal of all LNs in N1 and N2 stations. The perigastric LNs near lesser curvature (stations 1, 3, and 5) and greater curvature (stations 2, 4, and 6) were grouped together as N1 station. LNs near left gastric artery (station 7), common hepatic artery (station 8), celiac artery (station 9), and splenic artery (stations 10 and 11) were grouped together as N2 station.

If the LNs around spleen or splenic vessels were invaded by tumors, spleen would be excised, with an extra-vessel sheath lymphadenectomy performed meanwhile. All LNs were harvested immediately from the resected specimen by experienced surgeons, as the standard procedure [10]. All harvested LNs were evaluated by two experienced pathologists, and the accurate number of dissected and positive LNs was reported in postoperative day 5.

According to the total number of dissected LNs, all patients can be artificially categorized into five groups: 1–15 LNs (n = 74), 16–20 LNs (n = 53), 21–25 LNs (n = 45), 26–30 LNs (n = 36), and over 30 LNs (n = 92) groups. Besides, these patients can be divided into T1 (n = 90), T2 (n = 55), T3 (n = 117), and T4 (n = 38) groups according to the T stage classification.

All patients had routinely been followed up after operation every 3 months for the first year, every 6 months for the second year, and twice a year thereafter. The routine examination during followup included a physical examination, blood chemistry, CXR, ultrasound of liver and abdomen, and bone scan the tumor marker levels. The follow-up period ranged from the first day of therapy until death or the last visit. The last following time in this study was January 2012. The survival time ranged from the first diagnosis of gastric cancer until the last contact after surgery, the date of death, or the date that the survival information was collected. In sum, nine patients were lost in the followup and the follow-up rate is 96%.

2.3. Statistical Analyses. Data were expressed as mean ± SD if not indicating otherwise. The Kaplan-Meier method was used to investigate overall survival rate and potential prognostic factors. Factors associated with clinical outcomes were assessed by univariate analysis for quantitative variables and $\chi^2$ test for qualitative variables. Cox proportional hazards model was utilized in multivariate analysis. Spearman correlation analysis was used to evaluate the correlation between the number of dissected LNs and survival time. The stepwise logistic regression was performed to evaluate the correlation between the number of dissected LNs and the incidence of postoperative complication. A $P < 0.05$ was considered statistically significant.

3. Results

3.1. Clinical and Pathological Data. A total of 300 patients (M : F, 16:1) were included in the final analysis, with average age of 56.3 (range: 26–81) years. Among this cohort, 7786 pieces of LNs were harvested during surgery (mean 26, range 10–91). The characteristics of enrolled subjects are shown in Table 1. There were no significant differences in age, gender, and tumor size or stage among the five different categorized groups. However, tumor location and depth of invasion had significant differences ($P < 0.05$).

3.2. Correlation between Dissected LNs and Clinical Outcomes. The clinical outcomes of all patients after surgery are shown in Table 2. There was no significant correlation between number of dissected LNs with time of operation ($P = 0.621$), volume of transfusion ($P = 0.571$), length of stay in hospital ($P = 0.634$), and incidence of postoperative complication ($P = 0.228$).

3.3. Univariate and Multivariate Survival Analyses. The average overall survival time of GC patients was 50.2 ± 30.5 months. By Cox proportional hazard analysis, cancer-specific survival was significantly correlated with number of dissected LNs ($P < 0.001$) and depth of tumor invasion ($P = 0.001$), but not related to age, gender, tumor size, tumor location, histological type, or grading (Table 3). By further multivariate regression, the two factors were considered as independent factors of survival for GC patients without LN metastasis.

3.4. Correlation between Examined LNs Number and Postoperative Complication. During the follow-up period, 12 patients (4%) suffered from postoperative complications, with one
### Table 1: Overall survival univariate analysis for predictive factors of survival.

| Variables                  | Number, n (%) | Survival, Mo | $\chi^2$ value | $P$ value |
|----------------------------|---------------|--------------|----------------|-----------|
| Gender                     |               |              |                |           |
| Male                       | 205 (68.3%)   | 51.2 ± 27.3  | 0.912          | 0.364     |
| Female                     | 95  (31.7%)   | 48.5 ± 26.7  |                |           |
| Age (years)                |               |              | 2.562          | 0.195     |
| <60                        | 172 (57.3%)   | 45.5 ± 24.6  |                |           |
| ≥60                        | 128 (42.7%)   | 50.7 ± 30.1  |                |           |
| Tumor Size (cm)            |               |              | 0.352          | 0.624     |
| < 4                        | 185 (61.7%)   | 50.4 ± 27.2  |                |           |
| ≥4                         | 115 (38.3%)   | 46.5 ± 23.4  |                |           |
| Tumor Location             |               |              | 4.256          | 0.405     |
| Upper third                | 42 (14.0%)    | 42.2 ± 27.7  |                |           |
| Middle third               | 52  (17.3%)   | 46.4 ± 27.2  |                |           |
| Lower third                | 206 (68.7%)   | 48.8 ± 32.7  |                |           |
| T Category                 |               |              | 41.012         | <0.001    |
| T1                         | 90  (30.0%)   | 46.1 ± 29.1  |                |           |
| T2                         | 55  (18.3%)   | 48.9 ± 31.2  |                |           |
| T3                         | 117 (39.0%)   | 53.0 ± 31.0  |                |           |
| T4                         | 38  (12.7%)   | 55.0 ± 31.4  |                |           |
| Histopathological type     |               |              | 15.375         | 0.079     |
| Adenocarcinoma             | 249 (83.0%)   | 41.3 ± 25.5  |                |           |
| Mucinous adenocarcinoma    | 21  (7.0%)    | 44.3 ± 18.4  |                |           |
| Signet ring cell carcinoma | 30  (10.0%)   | 49.5 ± 14.5  |                |           |
| Histopathological grading  |               |              | 25.654         | 0.125     |
| Well/medicated differentiated | 199 (66.3%) | 53.2 ± 24.7  |                |           |
| Poor/undifferentiated      | 101 (33.7%)   | 46.2 ± 26.7  |                |           |
| Examined Lymph nodes, n    |               |              | 46.23          | <0.001    |
| 1–15                       | 74  (24.7%)   | 43.7 ± 28.0  |                |           |
| 16–20                      | 53  (17.7%)   | 48.4 ± 25.5  |                |           |
| 21–25                      | 45  (15.0%)   | 52.7 ± 32.8  |                |           |
| 26–30                      | 36  (12.0%)   | 62.0 ± 31.3  |                |           |
| ≥30                        | 92  (30.6%)   | 49.7 ± 31.8  |                |           |

Data in survival present with median ± SD. Chi-square test was used to compare the categorical variables. $P < 0.05$ considered statistically significant.

### Table 2: Correlation between number of examined lymph nodes and clinical outcomes.

| Variables                  | Overall  | 1–15     | 16–20    | 21–25    | 26–30    | > 30     | $\chi^2(F)$ value | $P$ value |
|----------------------------|----------|----------|----------|----------|----------|----------|-------------------|-----------|
| Hospital stay, day         | 15.0 ± 6.5| 12.0 ± 5.5| 13.5 ± 4.8| 14.1 ± 6.5| 16.1 ± 6.2| 15.5 ± 4.8| 0.431             | 0.634     |
| Transfusion volume, ML     | 207.4 ± 400.4| 188.3 ± 200.4| 166.0 ± 66.9| 120 ± 253.6| 213.9 ± 398.7| 248 ± 453| 0.536             | 0.571     |
| Operation time, min        | 266.3 ± 68.5| 201.3 ± 56.4| 266.3 ± 166.0| 274.9 ± 57.5| 273.3 ± 72.2| 265 ± 72   | 0.576             | 0.621     |
| Postop. Complication, n (%) | 288 (96.0%)| 72 (97.3%)| 51 (96.2%)| 43 (95.6%)| 34 (94.4%)| 88 (95.7%)| 3.423             | 0.228     |

Data present as mean ± SD without specific statement. Postop: postoperative; chi-square test was performed to compare differences.

For patients with T1 tumors, no significant correlation was found between the two factors. For patients beyond T1 stage,
disease-specific survival rate in GC patients beyond T1 stage. There was no consensus on the optimal number of examined LNs for GC. However, there is no standardized pathological N category for gastric cancer. Additionally, LN metastasis is one of the most crucial indicators of poor prognosis for patients with resectable gastric cancer. Furthermore, the location and total number of examined LNs are independent factors in predicting survival of patients with gastric cancer. Previous studies have shown that total number of examined LNs was associated with postoperative pathological grading and overall survival. Properly increasing the number of examined LNs during surgery could further improve the accuracy of pathological grading, which is helpful in prolonging survival time in GC patients beyond T1 stage.

LN metastasis is one of the most crucial indicators of poor prognosis for patients with resectable gastric cancer. Furthermore, the location and total number of examined LNs are independent factors in predicting survival of patients with gastric cancer. Previous studies have shown that total number of examined LNs was associated with postoperative pathological grading and overall survival. Properly increasing the number of examined LNs during surgery could further improve the accuracy of pathological grading, which is helpful in prolonging survival time in GC patients beyond T1 stage. Additionally, LN metastasis rate is recommended to be considered as a prognostic factor of gastric cancer [13]. However, there is no consensus on the optimal number of examined LNs for GC patients with various T stages. Recently, a study indicated that at least 16 negative LNs had a strong correlation with the best disease-specific survival rate in GC patients beyond T1 stage [14].

It has been confirmed that LN-negative GC has similar clinicopathological features to early GC [15]. It was reported that the 5-year survival rate of LN-negative GC after curative gastrectomy plus D2 lymphadenectomy was 89.5% [16]. Besides, an insufficient amount of dissected LNs could lead to an unreliable pathological grading, and over 15 examined LNs were associated with improved prognosis of LN-negative GC compared with less than 15 dissected LNs [6]. Furthermore, an insufficient (<15) examined LNs number, even in early GC with T1 stage, was associated with a poor prognosis [17]. It has shown that increased number of examined LNs can reduce stage deviation and guide decision making for chemotherapy [2, 3, 8, 17]. On the other hand, LN micrometastasis may result in the inaccuracy of pathological N category [18, 19]. Therefore, increasing the number of examined LNs during surgery could reduce the chance of residual malignancy and improve the prognosis of gastric cancer.

In this study, patients who had gastric cancer without LN metastasis and underwent curative operation were retrospectively reviewed. However, due to individual pathological conditions and various surgeon's preferences, there was a wide difference in dissected LNs number among all patients [20, 21]. As previously reported, older age and immune compromise were factors that might lead to an insufficient number of dissected LN [21, 22]. In our study, our results indicated that total number of dissected LNs and tumor invasion depth were independent prognostic factors of LN-negative GC. Actually, only the number of harvested LNs can be controlled by surgeons during operation. Hence, under current surgical skills and diagnostic techniques, it must be essential for surgeon to increase the total number of examined LNs when performing D2 lymphadenectomy.

The prognostic predictive value of total LN dissected number in survival of LN-negative GC had been reported, but no common consensus has been reached yet. Actually, the core problem focused on determination of optimal number of examined LNs during operation. Bovier's study suggested that a reliable staging for LN-negative GC required at least 10 dissected LNs [23]. However, in his study, patients included for analysis mainly underwent D1 lymphadenectomy rather than D2 procedure as our study. It has been a controversial issue whether D1 or D2 operation should be considered as the standard procedure for advanced gastric cancer [24, 25]. Biffi and other colleagues suggested that at least 15 LNs should be dissected for LN-negative GC [6]. Baiocchi et al. reported that the total number of dissected LNs was related to the prognosis of LN-negative GC, with the highest survival rate achieved when at least 25 LNs harvested [26]. In our study, our results were in accordance with those of Baiocchi et al.

It has been proven that the total number of examined LNs is significantly related to the prognosis of patients with advanced gastric cancer [5]. In our study, we performed a stratified analysis according to T stage and found that the increased number of examined LNs was in proportion to the increased survival time for LN-negative advanced gastric cancer beyond T1 stage. However, this trend was not observed when the number of examined LNs exceeded 30.

In addition, the total number of examined LNs was also significantly related to the prognosis of early gastric cancer [17]. However, our study did not find a similar result. It has been reported that the LN metastasis rate in GC patient with T1 stage was 15–20% [27]. For such populations, there is no consensus on the recognized number of LNs examined during operation. Considering the difficulty of preoperative T staging, we still recommend that at least 15 LNs should be examined for early stage gastric cancer.

Several studies have suggested that postoperative complications were not correlated with the number of dissected LNs during surgery [28–30]. Those complications, such as anastomotic fistula, hemorrhage, and intestinal obstruction, were possibly related to surgeon's skills and perioperative management, rather than the range of LN dissection. In current study, the incidence of postoperative complications was not related to LNs dissected number, operation time,

### Table 3: Prognostic factors retained in multivariate analysis.

| Factors                      | P value | Relative risk | 95% CI  |
|------------------------------|---------|---------------|---------|
| Invasion depth               | <0.001  | 1.704         | 1.418–2.048 |
| No. of examined lymph nodes  | <0.001  | 1.616         | 1.468–1.779 |

Cox proportional hazard analysis was used to investigate the potential prognostic factors of survival in GC patients without lymph node metastasis.

In the present study, the findings indicate that the GC-specific survival for patients without LN metastasis was significantly correlated with the depth of tumor invasion and the number of dissected LNs during surgery. By subgroup analysis, increased number of dissected LNs was found to be helpful in predicting survival for patients without LN metastasis [2, 11, 12].

The number of examined LNs was associated with postoperative pathological grading, which is helpful in prediction of survival for GC patients [2, 11, 12].

The UICC/AJCC TNM classification recommends that at least 15 LNs should be examined to accurately evaluate pathological N category of gastric cancer. Additionally, LN metastasis is recommended to be considered as a prognostic factor of gastric cancer [13]. However, there is no consensus on the optimal number of examined LNs for GC patients with various T stages. Recently, a study indicated that at least 16 negative LNs had a strong correlation with the best disease-specific survival rate in GC patients beyond T1 stage [14].

It has been confirmed that LN-negative GC has similar clinicopathological features to early GC [15]. It was reported that the 5-year survival rate of LN-negative GC after curative gastrectomy plus D2 lymphadenectomy was 89.5% [16]. Besides, an insufficient amount of dissected LNs could lead to an unreliable pathological grading, and over 15 examined LNs were associated with improved prognosis of LN-negative GC compared with less than 15 dissected LNs [6]. Furthermore, an insufficient (<15) examined LNs number, even in early GC with T1 stage, was associated with a poor prognosis [17]. It has shown that increased number of examined LNs can reduce stage deviation and guide decision making for chemotherapy [2, 3, 8, 17]. On the other hand, LN micrometastasis may result in the inaccuracy of pathological N category [18, 19]. Therefore, increasing the number of examined LNs during surgery could reduce the chance of residual malignancy and improve the prognosis of gastric cancer.

In this study, patients who had gastric cancer without LN metastasis and underwent curative operation were retrospectively reviewed. However, due to individual pathological conditions and various surgeon's preferences, there was a wide difference in dissected LNs number among all patients [20, 21]. As previously reported, older age and immune compromise were factors that might lead to an insufficient number of dissected LN [21, 22]. In our study, our results indicated that total number of dissected LNs and tumor invasion depth were independent prognostic factors of LN-negative GC. Actually, only the number of harvested LNs can be controlled by surgeons during operation. Hence, under current surgical skills and diagnostic techniques, it must be essential for surgeon to increase the total number of examined LNs when performing D2 lymphadenectomy.
transfusion volume, or postoperative hospital stay. Therefore, properly increasing the number of dissected LNs during surgery would not increase the risk of postoperative complications for LN-negative GC.

In conclusion, our results indicate that 26–30 of dissected LNs from resected tumors during standard gastrectomy with D2 lymphadenectomy could increase overall survival of LN-negative GC. Properly increasing the number of harvested LNs during surgery is a safe procedure and would not increase the incidence of postoperative complications.

**Conflict of Interests**

All authors have declared no conflict of interests.

**Authors’ Contribution**

Wu Song and Yujie Yuan contributed equally to this study.

**References**

[1] L. Sobin, M. Gospodarowicz, and C. Wittekind, *International Union against Cancer (UICC) TNM Classification of Malignant Tumours*, Wiley, New York, NY, USA, 7th edition, 2010.

[2] G. de Manzoni, G. Verlato, F. Roviello et al., “The new TNM classification of lymph node metastasis minimizes stage migration problems in gastric cancer patients,” *British Journal of Cancer*, vol. 87, no. 2, pp. 171–174, 2002.

[3] K. Inoue, Y. Nakane, H. Iiyama et al., “The superiority of ratio-based lymph node staging in gastric carcinoma,” *Annals of Surgical Oncology*, vol. 9, no. 1, pp. 27–34, 2002.

[4] Strong VEI, T. A. D’Amico, L. Kleinberg, and J. Ajani, “Impact of the 7th edition AJCC staging classification on the NCCN clinical practice guidelines in oncology for gastric and esophageal cancers,” *Journal of the National Comprehensive Cancer Network*, vol. 11, no. 1, pp. 60–66, 2013.

[5] R. E. Schwarz and D. D. Smith, “Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage,” *Annals of Surgical Oncology*, vol. 14, no. 2, pp. 317–328, 2007.

[6] R. Biffi, E. Botteri, S. Cenciarelli et al., “Impact on survival of the number of lymph nodes removed in patients with node-negative gastric cancer submitted to extended lymph node dissection,” *European Journal of Surgical Oncology*, vol. 37, no. 4, pp. 305–311, 2011.

[7] S. Edge, D. Byrd, C. Compton et al., *AJCC Cancer Staging Manual*, Springer, New York, NY, USA, 7th edition, 2010.

[8] N. G. Coburn, C. J. Swallow, A. Kiss, and C. Law, “Significant regional variation in adequacy of lymph node assessment and survival in gastric cancer,” *Cancer*, vol. 107, no. 9, pp. 2143–2151, 2006.

[9] A. Giuliani, A. Caporale, M. Corona et al., “Lymphadenectomy in gastric cancer: influence on prognosis of lymph node count,” *Journal of Experimental and Clinical Cancer Research*, vol. 23, no. 2, pp. 215–224, 2004.

[10] Y. Sakamoto, Y. Sakaguchi, M. Sugiyama, K. Minami, Y. Toh, and T. Okamura, “Surgical indications for gastrectomy combined with distal or partial pancreatectomy in patients with gastric cancer,” *World Journal of Surgery*, vol. 36, no. 10, pp. 2412–2419, 2012.

[11] W. Wang, D. Z. Xu, Y. F. Li et al., “Tumor-ratio-metastasis staging system as an alternative to the 7th edition UICC TNM system in gastric cancer after D2 resection: results of a singleinstitution study of 1343 Chinese patients,” *Annals of Oncology*, vol. 22, no. 9, pp. 2049–2056, 2011.

[12] H. Takeuchi and Y. Kitagawa, “Is lymphadenectomy a predictor or savior for patients with gastric cancer?” *Annals of Surgical Oncology*, vol. 17, no. 5, pp. 1257–1258, 2010.

[13] A. Latengbaolide, D. Lin, Y. Li et al., “Lymph node ratio is an independent prognostic factor in gastric cancer after curative Resection (R0) regardless of the examined number of lymph nodes,” *The American Journal of Clinical Oncology*, vol. 36, no. 4, pp. 325–330, 2013.

[14] D. Xu, Y. Huang, Q. Geng et al., “Effect of lymph node number on survival of patients with lymph node-negative gastric cancer according to the 7th edition UICC TNM system,” *PLoS ONE*, vol. 7, Article ID e38681, 2012.

[15] J. Deng, H. Liang, D. Sun, D. Wang, and Y. Pan, “Suitability of 7th UICC N stage for predicting the overall survival of gastric cancer patients after curative resection,” *Annals of Surgical Oncology*, vol. 17, no. 5, pp. 1259–1266, 2010.

[16] C. W. Wu, M. C. Hsieh, S. S. Lo, S. H. Tsay, W. Y. Lui, and E. K. P’eng, “Relation of number of positive lymph nodes to the prognosis of patients with primary gastric adenocarcinoma,” *Gut*, vol. 38, no. 4, pp. 525–527, 1996.

[17] T. Son, W. J. Hyung, J. H. Lee et al., “Clinical implication of an insufficient number of examined lymph nodes after curative resection for gastric cancer,” *Cancer*, vol. 118, no. 19, pp. 4687–4693, 2012.

[18] Z.-Y. Wu, J. Wan, J.-H. Li et al., “Prognostic value of lateral lymph node metastasis for advanced low rectal cancer,” *World Journal of Gastroenterology*, vol. 13, no. 45, pp. 6048–6052, 2007.

[19] P. Morgagni, L. Saragoni, E. Scarpi et al., “Lymph node micrometastases in early gastric cancer and their impact on prognosis,” *World Journal of Surgery*, vol. 27, no. 5, pp. 558–561, 2003.
[20] D. K. Dhar, H. Kubota, M. Tachibana et al., “Body mass index determines the success of lymph node dissection and predicts the outcome of gastric carcinoma patients,” Oncology, vol. 59, no. 1, pp. 18–23, 2000.

[21] V. Dudeja, E. B. Habermann, W. Zhong et al., “Guideline recommended gastric cancer care in the elderly: insights into the applicability of cancer trials to real world,” Annals of Surgical Oncology, vol. 18, no. 1, pp. 26–33, 2011.

[22] N. N. Baxter and T. M. Tuttle, “Inadequacy of lymph node staging in gastric cancer patients: a population-based study,” Annals of Surgical Oncology, vol. 12, no. 12, pp. 981–987, 2005.

[23] A.-M. Bouvier, O. Haas, F. Piard, P. Roignot, C. Bonithon-Kopp, and J. Faire, “How many nodes must be examined to accurately stage gastric carcinomas?: results from a population based study,” Cancer, vol. 94, no. 11, pp. 2862–2866, 2002.

[24] I. Songun, H. Putter, E. M.-K. Kranenburg, M. Sasako, and C. J. van de Velde, “Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial,” The Lancet Oncology, vol. 11, no. 5, pp. 439–449, 2010.

[25] C.-W. Wu, C. A. Hsiung, S.-S. Lo et al., “Nodal dissection for patients with gastric cancer: a randomised controlled trial,” The Lancet Oncology, vol. 7, no. 4, pp. 309–315, 2006.

[26] G. L. Baiocchi, G. A. Tiberio, A. M. Minicozzi et al., “A multicentric western analysis of prognostic factors in advanced, node-negative gastric cancer patients,” Annals of Surgery, vol. 252, no. 1, pp. 70–73, 2010.

[27] S. A. Hundahl, J. L. Phillips, and H. R. Menck, “The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: fifth Edition American Joint Committee on Cancer staging, proximal disease, and the, “different disease” hypothesis,” Cancer, vol. 88, no. 4, pp. 921–932, 2000.

[28] B. Zilberstein, B. da Costa Martins, C. E. Jacob et al., “Complications of gastrectomy with lymphadenectomy in gastric cancer,” Gastric Cancer, vol. 7, no. 4, pp. 254–259, 2004.

[29] C. W. Wu, C. A. Hsiung, S. S. Lo, M. C. Hsieh, L. T. Shia, and J. Whang-Peng, “Randomized clinical trial of morbidity after D1 and D3 surgery for gastric cancer,” British Journal of Surgery, vol. 91, no. 3, pp. 283–287, 2004.

[30] M. Sasako, T. Sano, S. Yamamoto et al., “D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer,” The New England Journal of Medicine, vol. 359, no. 5, pp. 453–462, 2008.